SoFi Technologies SOFI is entering a different phase of its lifecycle, where operating leverage is becoming a visible driver ...

Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180 ...

Stern provided forward-looking guidance: "In the fourth quarter, we expected net interest income on a fully taxable equivalent basis to be relatively stable to our third quarter level of $4.25 billion ...